Trial Profile

Understanding Mechanisms of Acquired Resistance to BIBW2992.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Afatinib (Primary)
Indications Non-small cell lung cancer
Focus Pharmacogenomic; Therapeutic Use

Most Recent Events

10 Mar 2017 Status changed from active, no longer recruiting to completed.
14 Nov 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jan 2017.
03 Nov 2014 Planned End Date changed from 1 Mar 2015 to 1 Mar 2017, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com